Avoiding patient morbidity

Updated statin drug interactions and risks for patient harm

Shannon Finks, Jennifer D. Campbell

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Almost 50% of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes of particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.

Original languageEnglish (US)
Pages (from-to)45-51
Number of pages7
JournalNurse Practitioner
Volume39
Issue number11
DOIs
StatePublished - Jan 1 2014

Fingerprint

Patient Harm
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Drug Interactions
Morbidity
Product Labeling
Simvastatin
Drug Combinations
Cytochrome P-450 Enzyme System
Kidney
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Nursing(all)
  • Medicine(all)

Cite this

Avoiding patient morbidity : Updated statin drug interactions and risks for patient harm. / Finks, Shannon; Campbell, Jennifer D.

In: Nurse Practitioner, Vol. 39, No. 11, 01.01.2014, p. 45-51.

Research output: Contribution to journalReview article

@article{d560bb4b86ca428d92ebd308f20168f9,
title = "Avoiding patient morbidity: Updated statin drug interactions and risks for patient harm",
abstract = "Almost 50{\%} of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes of particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.",
author = "Shannon Finks and Campbell, {Jennifer D.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/01.NPR.0000443232.02852.f8",
language = "English (US)",
volume = "39",
pages = "45--51",
journal = "Nurse Practitioner",
issn = "0361-1817",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Avoiding patient morbidity

T2 - Updated statin drug interactions and risks for patient harm

AU - Finks, Shannon

AU - Campbell, Jennifer D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Almost 50% of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes of particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.

AB - Almost 50% of serious adverse events with statin therapy are attributed to unfavorable drug-drug combinations. This article reviews updated FDA warnings on capping the dose of simvastatin, recent package insert labeling changes of particular statins that address combinations with potent cytochrome P450 inhibitors, and current renal dosing recommendations for statins.

UR - http://www.scopus.com/inward/record.url?scp=84920939045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920939045&partnerID=8YFLogxK

U2 - 10.1097/01.NPR.0000443232.02852.f8

DO - 10.1097/01.NPR.0000443232.02852.f8

M3 - Review article

VL - 39

SP - 45

EP - 51

JO - Nurse Practitioner

JF - Nurse Practitioner

SN - 0361-1817

IS - 11

ER -